The Impact of Semaglutide Compared to Energy Restriction on Type 2 Diabetes

NCT07272343 · Recruiting

Last updated 2026-05-28

This clinical trial compares the effects of the medication semaglutide to calorie restriction on people with type 2 diabetes.

Status Recruiting Currently enrolling participants.

Phase Phase 4 Monitors a drug already on the market.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 100 people Planned (estimated).

Who can join Ages 18–75 · all sexes

Timeline Started 2023-02 · est. completion 2026-07

Where 1 site · China

What this study is testing ClinicalTrials.gov NCT07272343 ↗

Description as written by the study sponsor.

To evaluate the effects of subcutaneous injection of semaglutide for 12 weeks on patients with type 2 diabetes mellitus (T2DM), compared with concurrent energy-restricted management, on glycemic control, weight loss, inflammatory markers, liver fat content, and other parameters. The study also observed the subcutaneous and visceral fat of the participants and explored the molecular mechanisms of action, providing high-quality evidence-based support for the timing and targets of intervention in this population.

Treatments tested

semaglutide Drug

The semaglutide group received weekly subcutaneous semaglutide (0.25 mg for weeks 1-2, 0.5 mg for weeks 3-4, and 1.0 mg for weeks 5-12).
caloric restriction Behavioral

The caloric restriction group followed a gender-specific daily caloric restriction (1,500-1,800 kcal for males; 1,200-1,500 kcal for females).

Main thing measured	HbA1c
Sponsor	Second Affiliated Hospital of Nanchang University
Conditions studied	Type 2 Diabetes Mellitus (T2DM), Semaglutide, Caloric Restriction
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07272343 ↗